SG11202107238UA - Method of detecting a neurodegenerative disease - Google Patents
Method of detecting a neurodegenerative diseaseInfo
- Publication number
- SG11202107238UA SG11202107238UA SG11202107238UA SG11202107238UA SG11202107238UA SG 11202107238U A SG11202107238U A SG 11202107238UA SG 11202107238U A SG11202107238U A SG 11202107238UA SG 11202107238U A SG11202107238U A SG 11202107238UA SG 11202107238U A SG11202107238U A SG 11202107238UA
- Authority
- SG
- Singapore
- Prior art keywords
- detecting
- neurodegenerative disease
- neurodegenerative
- disease
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/55—Specular reflectivity
- G01N21/552—Attenuated total reflection
- G01N21/553—Attenuated total reflection and using surface plasmons
- G01N21/554—Attenuated total reflection and using surface plasmons detecting the surface plasmon resonance of nanostructured metals, e.g. localised surface plasmon resonance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/553—Metal or metal coated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201900940Y | 2019-01-31 | ||
PCT/IB2020/050764 WO2020157705A1 (en) | 2019-01-31 | 2020-01-30 | Method of detecting a neurodegenerative disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202107238UA true SG11202107238UA (en) | 2021-07-29 |
Family
ID=71841387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202107238UA SG11202107238UA (en) | 2019-01-31 | 2020-01-30 | Method of detecting a neurodegenerative disease |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220397580A1 (en) |
EP (1) | EP3918327A4 (en) |
JP (1) | JP2022519583A (en) |
CN (1) | CN113614531A (en) |
SG (1) | SG11202107238UA (en) |
WO (1) | WO2020157705A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023080102A1 (en) * | 2021-11-04 | 2023-05-11 | 凸版印刷株式会社 | METHOD FOR DETECTING AMYLOID-β BOUND TO BRAIN-NEURONAL-CELL-DERIVED EXOSOME IN BLOOD, KIT FOR DETECTION OF AMYLOID-β BOUND TO BRAIN-NEURONAL-CELL-DERIVED EXOSOME IN BLOOD, AND METHOD FOR EVALUATING ACCUMULATION LEVEL OF AMYLOID-β IN BRAIN |
WO2023232108A1 (en) * | 2022-06-02 | 2023-12-07 | 浙江大学医学院附属第一医院 | Method, system, composition, and kit for diagnosing and identifying non-alzheimer's disease cognitive disorder |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2963791B1 (en) * | 2010-08-11 | 2012-09-21 | Assist Publ Hopitaux De Paris | METHOD OF DIAGNOSING NEURODEGENERATIVE DISEASES |
JP6074746B2 (en) * | 2011-10-14 | 2017-02-08 | 国立大学法人北海道大学 | Drug for amyloid β-related diseases and screening thereof |
CA2926092A1 (en) * | 2013-10-24 | 2015-04-30 | Nanosomix, Inc. | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders |
CN106062559B (en) * | 2014-06-27 | 2018-12-14 | 北京新源长青生物科技有限公司 | Method for being enriched with the excretion body in the source CNS |
WO2016201323A1 (en) * | 2015-06-10 | 2016-12-15 | Board Of Regents, The University Of Texas System | Use of exosomes for the treatment of disease |
WO2017087467A1 (en) * | 2015-11-20 | 2017-05-26 | Exosome Sciences, Inc. | Exosomal tau as a biomarker for brain disorders |
US11243215B2 (en) * | 2016-01-14 | 2022-02-08 | The Regents Of The University Of California | 3D-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids |
EP3452828A4 (en) * | 2016-05-06 | 2019-12-04 | Nanosomix Inc. | Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders |
KR102048987B1 (en) * | 2017-02-22 | 2019-11-27 | 한국과학기술연구원 | Information providing method for identification of neurodegenerative disorder |
WO2018218090A1 (en) * | 2017-05-24 | 2018-11-29 | Nanosomix, Inc. | Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders |
-
2020
- 2020-01-30 JP JP2021544901A patent/JP2022519583A/en active Pending
- 2020-01-30 SG SG11202107238UA patent/SG11202107238UA/en unknown
- 2020-01-30 WO PCT/IB2020/050764 patent/WO2020157705A1/en unknown
- 2020-01-30 US US17/310,253 patent/US20220397580A1/en active Pending
- 2020-01-30 CN CN202080012032.7A patent/CN113614531A/en active Pending
- 2020-01-30 EP EP20749564.9A patent/EP3918327A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020157705A1 (en) | 2020-08-06 |
CN113614531A (en) | 2021-11-05 |
JP2022519583A (en) | 2022-03-24 |
EP3918327A1 (en) | 2021-12-08 |
EP3918327A4 (en) | 2022-11-23 |
US20220397580A1 (en) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3781458C0 (en) | Method for determining a turning radius | |
IL243386A0 (en) | A method for extracting latent context patterns from sensors | |
GB201915444D0 (en) | Method of using a blockchain | |
GB201805954D0 (en) | A method | |
GB201804627D0 (en) | A method of communicating | |
GB201809450D0 (en) | Method for detecting a tandem repeat | |
SG11202107238UA (en) | Method of detecting a neurodegenerative disease | |
IL291367A (en) | Method for determining a field-of-view setting | |
GB201902908D0 (en) | Method of using a blockchain | |
GB201611652D0 (en) | Method of detecting a condition | |
SG11202006997SA (en) | A method of determining a risk of cancer | |
IL283892A (en) | A method for determining a chemotypic profile | |
IL280423A (en) | A method for identifying intermediates | |
IL276898A (en) | A method of detecting magea4 | |
SG11202105280QA (en) | Method of identifying a structure | |
SG11202105311VA (en) | Method of identifying a structure | |
EP3728280C0 (en) | Method for improving the oral bioavailability of a drug | |
GB201807651D0 (en) | A method of detection | |
GB201813722D0 (en) | A method | |
ZA202006375B (en) | A method of carbonizate purification | |
IL281333A (en) | Method of derisking a clinical trial | |
EP3647943C0 (en) | Method for determining at least one characteristic of at least a change | |
PL3316066T3 (en) | Method for determining at least a part of a border | |
GB201813730D0 (en) | A method | |
GB201809530D0 (en) | A method |